109
Participants
Start Date
June 22, 2022
Primary Completion Date
January 31, 2025
Study Completion Date
February 4, 2025
CardiolRx
Eligible patients will be randomized to receive CardiolRx or placebo. Intervention will be administered orally (via syringe) with food twice daily.
University of Pittsburgh Medical Center, Pittsburgh
MedStar Heart and Vascular Institute, Washington D.C.
Virginia Commonwealth University, Richmond
Centre Hospitalier Universitaire de Nîmes, Nîmes
CHU de Montpellier, Montpellier
Cleveland Clinic, Cleveland
Minneapolis Heart Institute Foundation, Minneapolis
Hopital Louis Pradel Hospices Civils de Lyon, Bron
Shamir Medical Center (Assaf Harofeh), Zrifin
Hôpital Lariboisière - Département de Cardiologie, Paris
Hôpital Foch, Suresnes
Beilinson Hospital, Rabin medical Center, Petah Tikva
Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv
Barzilai Medical Center, Ashkelon
Shaare Zedek Medical Center, Jerusalem
Nupec-Orizonti, Belo Horizonte
Massachusetts General Hospital site, Boston
PUC trials, Curitiba
Complexo Hospitalar de Niterói, Niterói
Hospital Moinhos de Vento, Porto Alegre
Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre
Hospital Nove de Julho, São Paulo
Hospital Felicio Rocho - Fundação Felice Rosso, Belo Horizonte
Hospital Angelina Caron, Campina Grande do Sul
Hospital São Lucas, Porto Alegre
Hospital Pró-Cardíaco, Rio de Janeiro
Hospital Regional de São José, São José
Instituto do Coração - InCor, São Paulo
Hopital Bichat Claude Bernard, Paris
Hôpital européen Georges-Pompidou, Paris
Institut de Cardiologie hopital Pitié Salpêtrière, Paris
Centre Hospitalier Universitaire de Poitiers, Poitiers
Chu Rangueil, Toulouse
Instituto D´Or de Pesquisa e Ensino, Rio de Janeiro
Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo
University of Alberta Hospital, Edmonton
McGill University Health Centre, Montreal
Lead Sponsor
Cardiol Therapeutics Inc.
INDUSTRY